Statistical Collaborative, which is based in Washington, D.C., US, provides biostatistical consulting services to companies developing new drugs and biologics.
In particular, the company offers expertise in trial design, reporting for data monitoring committees, data analysis, and consultation for US Food and Drug Administration presentations. It also works with companies when designing preclinical studies and non-clinical research.
Through the acquisition, WCG will take onboard all of Statistics Collaboration’s staff members and retain the same leadership structure. While the company name will change to simply be prefixed by ‘WCG’.
The financial details of the deal were not disclosed, but WCG will provide its new subsidiary with “access to capital, additional clinical development expertise, and corporate operational support,” WCG stated.
For WCG, the strategy continues where 2019 left off – as it consistently adds to its solutions through small-scale acquisitions, year-on-year.